Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Revenue (2016 - 2025)

OptimizeRx's Revenue history spans 16 years, with the latest figure at $26.1 million for Q3 2025.

  • For Q3 2025, Revenue rose 22.33% year-over-year to $26.1 million; the TTM value through Sep 2025 reached $109.5 million, up 24.18%, while the annual FY2024 figure was $92.1 million, 28.81% up from the prior year.
  • Revenue for Q3 2025 was $26.1 million at OptimizeRx, down from $29.2 million in the prior quarter.
  • Across five years, Revenue topped out at $32.3 million in Q4 2024 and bottomed at $11.2 million in Q1 2021.
  • The 5-year median for Revenue is $18.8 million (2024), against an average of $19.2 million.
  • The largest annual shift saw Revenue dropped 6.45% in 2022 before it soared 55.19% in 2025.
  • A 5-year view of Revenue shows it stood at $20.3 million in 2021, then decreased by 3.24% to $19.7 million in 2022, then soared by 44.34% to $28.4 million in 2023, then grew by 13.91% to $32.3 million in 2024, then dropped by 19.34% to $26.1 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Revenue are $26.1 million (Q3 2025), $29.2 million (Q2 2025), and $21.9 million (Q1 2025).